Gene or Genome – Page 19

Merck and Daiichi Sankyo Collaborate to Develop T-Cell Engager MK-6070 from Harpoon Acquisition

10 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3 gene, Harpoon, Immunostimulating conjugate (antigen), Merck, MK-6070, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck, Daiichi Sankyo, T-cell engager, MK-6070, Harpoon Therapeutics, small cell lung cancer, DLL3, antibody-drug conjugates

Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus

10 months ago talkbio0Tagged Agenus, Dosage Forms, licensing agreement, Myers, squibb, TIGIT gene

Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal

Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency

10 months ago talkbio0Tagged ADAR gene, Airna, alpha 1-Antitrypsin Deficiency, Alpha-1, Antitrypsin Deficiency, Clustered Regularly Interspaced Short Palindromic Repeats, Genetic Medicine, RNA Editing, RNA therapy, startup

Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy

FDA Criticizes Brittany Mahomes’ Paid Instagram Post for Kaléo’s Auvi-Q

10 months ago talkbio0Tagged Advertisements, ANOS1 gene, Auvi-Q, Brittany Mahomes, pharmaceutical marketing, Social Media, United States Food and Drug Administration

FDA, Brittany Mahomes, Kaléo, Auvi-Q, misleading advertisement, social media regulation, pharmaceutical marketing

BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.

10 months ago talkbio0

, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,

Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials

10 months ago talkbio0Tagged Carcinoma of anal margin, Incyte, Inhibitor, Non-Small Cell Lung Carcinoma, PDCD1 gene, Phase 3, Zynyz

Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer

BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111

10 months ago talkbio0Tagged BioNTech, Cancer Therapeutic Procedure, cemiplimab, checkpoint inhibitor, melanoma, mRNA immunotherapy, mRNA-LPX technology, PDCD1 gene, Phase 2 trial, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, uridine

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology

Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease

10 months ago talkbio0Tagged Biosciences, Crohn 's disease, Drug Development, Failure (biologic function), Inhibitor, Phase 2 Clinical Trials, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure

Ventyx Discontinues TYK2 Inhibitor Programme Following Second Mid-Stage Setback

11 months ago talkbio0Tagged Arthritis, Psoriatic, Biosciences, Crohn 's disease, Drug Development, Inflammatory disorder, Inhibitor, Phase 2 Failure, Psoriasis, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Phase 2 failure, psoriasis, psoriatic arthritis, Crohn’s disease, inflammatory diseases, drug development.

AstraZeneca’s New Calquence Combinations Show Promise in CLL Treatment: Potential to Shift Clinical Practice

11 months ago talkbio0Tagged AstraZeneca, BTK gene, Calquence, Chronic Lymphocytic Leukemia, Clinical Practice, CLL, Fixed-Duration, Inhibitor, obinutuzumab, venetoclax

AstraZeneca, Calquence, CLL, Chronic Lymphocytic Leukaemia, BTK Inhibitor, Venetoclax, Obinutuzumab, Clinical Practice, Fixed-Duration Treatment